Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
Jonathan D. Schoenfeld(Brigham and Women's Hospital), Robert I. Haddad(Georgetown University), Jason L. Weirather(Dana-Farber Cancer Institute), Shana Criscitiello(Brigham and Women's Hospital), Kai W. Wucherpfennig(Dana-Farber Cancer Institute), Laura A. Goguen(Brigham and Women's Hospital), Glenn J. Hanna(Dana-Farber Cancer Institute), Adrienne Luoma(Harvard University), Jason Kass(Brigham and Women's Hospital), Donald J. Annino(Harvard University), Brendan Ross, Ana Lako(Brigham and Women's Hospital), Heather A. Jacene(Brigham and Women's Hospital), Scott J. Rodig(Brigham and Women's Hospital), Ravindra Uppaluri(Brigham and Women's Hospital), Bhupendra Rawal(Harvard University), Zoe Ciantra(Dana-Farber Cancer Institute), Roy B. Tishler(Dana-Farber Cancer Institute), Danielle N. Margalit(Harvard University), Paul Catalano(Harvard University), Yu‐Hui Chen(Dana-Farber Cancer Institute), Anupam M. Desai(Beth Israel Deaconess Medical Center), Nicole G. Chau(University of British Columbia), Jochen H. Lorch(Northwestern University), Hina Shah(Harvard University), Vickie Y. Jo(Brigham and Women's Hospital)
Cited by 350
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k